# Topotecan in Treating Patients With Recurrent, Progressive, or Refractory Cancer That is Metastatic to the Lining Around the Brain

> **NCT00025311** · PHASE1 · COMPLETED · sponsor: **NYU Langone Health**

## Conditions studied

- Brain and Central Nervous System Tumors

## Interventions

- **DRUG:** topotecan hydrochloride

## Key facts

- **NCT ID:** NCT00025311
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-05
- **Primary completion:** 2003-10
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2012-11-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00025311

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00025311, "Topotecan in Treating Patients With Recurrent, Progressive, or Refractory Cancer That is Metastatic to the Lining Around the Brain". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00025311. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*